Show simple item record

dc.contributor.authorFyffe, C.
dc.contributor.authorBuus, R.
dc.contributor.authorFalasca, Marco
dc.date.accessioned2017-01-30T15:13:06Z
dc.date.available2017-01-30T15:13:06Z
dc.date.created2015-10-29T04:09:34Z
dc.date.issued2013
dc.identifier.citationFyffe, C. and Buus, R. and Falasca, M. 2013. Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms. Current Pharmaceutical Design. 19 (4): pp. 680-686.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/44263
dc.description.abstract

The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulation of PI3K isoforms is one of the most prominent. Emerging evidence Indicates that levels of isoforms can be modulated upon stimulation or in both physiological and pathological conditions including increased gene copy number and transcription regulation. In addition, an intriguing role for epigenetic regulation of PI3K expression, caused by mechanisms other than changes in the underlying DNA sequence, are starting to get appreciated. In this review, we summarize the genetic and epigenetic regulation of PI3Ks in physiology and the role played by their alterations in different diseases.

dc.titleGenetic and epigenetic regulation of phosphoinositide 3-kinase isoforms
dc.typeJournal Article
dcterms.source.volume19
dcterms.source.number4
dcterms.source.startPage680
dcterms.source.endPage686
dcterms.source.issn1381-6128
dcterms.source.titleCurrent Pharmaceutical Design
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record